vs

Side-by-side financial comparison of Goosehead Insurance, Inc. (GSHD) and MEDIFAST INC (MED). Click either name above to swap in a different company.

Goosehead Insurance, Inc. is the larger business by last-quarter revenue ($93.1M vs $75.1M, roughly 1.2× MEDIFAST INC). On growth, Goosehead Insurance, Inc. posted the faster year-over-year revenue change (23.1% vs -36.9%). Over the past eight quarters, Goosehead Insurance, Inc.'s revenue compounded faster (9.2% CAGR vs -34.4%).

Goosehead Insurance is a U.S.-based personal lines insurance agency that offers a wide range of coverage products including auto, home, renters, flood, and specialty insurance. It partners with hundreds of insurance carriers to provide clients with tailored, cost-effective coverage options, operating via corporate locations and a national franchise network for independent agents.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

GSHD vs MED — Head-to-Head

Bigger by revenue
GSHD
GSHD
1.2× larger
GSHD
$93.1M
$75.1M
MED
Growing faster (revenue YoY)
GSHD
GSHD
+60.0% gap
GSHD
23.1%
-36.9%
MED
Faster 2-yr revenue CAGR
GSHD
GSHD
Annualised
GSHD
9.2%
-34.4%
MED

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
GSHD
GSHD
MED
MED
Revenue
$93.1M
$75.1M
Net Profit
$8.0M
Gross Margin
69.4%
Operating Margin
16.1%
-10.4%
Net Margin
8.6%
Revenue YoY
23.1%
-36.9%
Net Profit YoY
204.0%
EPS (diluted)
$0.19
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GSHD
GSHD
MED
MED
Q1 26
$93.1M
Q4 25
$105.3M
$75.1M
Q3 25
$90.4M
$89.4M
Q2 25
$94.0M
$105.6M
Q1 25
$75.6M
$115.7M
Q4 24
$93.9M
$119.0M
Q3 24
$78.0M
$140.2M
Q2 24
$78.1M
$168.6M
Net Profit
GSHD
GSHD
MED
MED
Q1 26
$8.0M
Q4 25
$12.4M
Q3 25
$7.9M
$-2.3M
Q2 25
$5.2M
$2.5M
Q1 25
$2.3M
$-772.0K
Q4 24
$14.9M
Q3 24
$7.6M
$1.1M
Q2 24
$6.2M
$-8.2M
Gross Margin
GSHD
GSHD
MED
MED
Q1 26
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Operating Margin
GSHD
GSHD
MED
MED
Q1 26
16.1%
Q4 25
29.4%
-10.4%
Q3 25
23.5%
-4.6%
Q2 25
16.7%
-1.0%
Q1 25
8.8%
-1.1%
Q4 24
29.7%
0.6%
Q3 24
21.1%
1.5%
Q2 24
19.7%
-4.7%
Net Margin
GSHD
GSHD
MED
MED
Q1 26
8.6%
Q4 25
11.8%
Q3 25
8.7%
-2.5%
Q2 25
5.5%
2.3%
Q1 25
3.1%
-0.7%
Q4 24
15.8%
Q3 24
9.7%
0.8%
Q2 24
7.9%
-4.8%
EPS (diluted)
GSHD
GSHD
MED
MED
Q1 26
$0.19
Q4 25
$0.48
$-1.64
Q3 25
$0.29
$-0.21
Q2 25
$0.18
$0.22
Q1 25
$0.09
$-0.07
Q4 24
$0.58
$0.08
Q3 24
$0.29
$0.10
Q2 24
$0.24
$-0.75

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GSHD
GSHD
MED
MED
Cash + ST InvestmentsLiquidity on hand
$25.7M
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$-121.3M
$198.9M
Total Assets
$392.8M
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GSHD
GSHD
MED
MED
Q1 26
$25.7M
Q4 25
$34.4M
$167.3M
Q3 25
$51.6M
$173.5M
Q2 25
$92.4M
$162.7M
Q1 25
$70.2M
$164.6M
Q4 24
$54.3M
$162.3M
Q3 24
$47.5M
$170.0M
Q2 24
$23.6M
$163.5M
Total Debt
GSHD
GSHD
MED
MED
Q1 26
Q4 25
$289.5M
Q3 25
$290.0M
Q2 25
$289.8M
Q1 25
$290.3M
Q4 24
$82.3M
Q3 24
$84.6M
Q2 24
$87.0M
Stockholders' Equity
GSHD
GSHD
MED
MED
Q1 26
$-121.3M
Q4 25
$-95.5M
$198.9M
Q3 25
$-105.0M
$214.7M
Q2 25
$-78.6M
$216.0M
Q1 25
$-88.5M
$211.0M
Q4 24
$43.9M
$210.1M
Q3 24
$58.3M
$207.3M
Q2 24
$39.8M
$205.3M
Total Assets
GSHD
GSHD
MED
MED
Q1 26
$392.8M
Q4 25
$414.9M
$248.0M
Q3 25
$403.6M
$268.2M
Q2 25
$436.6M
$269.3M
Q1 25
$412.6M
$280.0M
Q4 24
$397.7M
$284.2M
Q3 24
$358.1M
$291.2M
Q2 24
$338.2M
$293.5M
Debt / Equity
GSHD
GSHD
MED
MED
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
1.87×
Q3 24
1.45×
Q2 24
2.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GSHD
GSHD
MED
MED
Operating Cash FlowLast quarter
$-5.3M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GSHD
GSHD
MED
MED
Q1 26
Q4 25
$91.8M
$-5.3M
Q3 25
$24.2M
$12.1M
Q2 25
$28.9M
$-3.4M
Q1 25
$15.5M
$3.4M
Q4 24
$71.5M
$-4.9M
Q3 24
$28.1M
$9.1M
Q2 24
$18.9M
$13.1M
Free Cash Flow
GSHD
GSHD
MED
MED
Q1 26
Q4 25
$86.1M
$-6.6M
Q3 25
$23.7M
$10.8M
Q2 25
$27.2M
$-4.8M
Q1 25
$14.9M
$1.9M
Q4 24
$70.6M
$-7.2M
Q3 24
$28.0M
$7.7M
Q2 24
$18.6M
$11.1M
FCF Margin
GSHD
GSHD
MED
MED
Q1 26
Q4 25
81.8%
-8.8%
Q3 25
26.2%
12.0%
Q2 25
28.9%
-4.5%
Q1 25
19.7%
1.6%
Q4 24
75.1%
-6.1%
Q3 24
35.9%
5.5%
Q2 24
23.9%
6.6%
Capex Intensity
GSHD
GSHD
MED
MED
Q1 26
Q4 25
5.4%
1.8%
Q3 25
0.5%
1.5%
Q2 25
1.8%
1.3%
Q1 25
0.8%
1.3%
Q4 24
1.0%
1.9%
Q3 24
0.1%
1.0%
Q2 24
0.3%
1.1%
Cash Conversion
GSHD
GSHD
MED
MED
Q1 26
Q4 25
7.38×
Q3 25
3.06×
Q2 25
5.61×
-1.36×
Q1 25
6.61×
Q4 24
4.82×
Q3 24
3.72×
8.04×
Q2 24
3.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GSHD
GSHD

Renewal Royalty Fees (2)$43.6M47%
Renewal Commissions (1)$18.2M20%
Contingent Commissions (1)$10.7M11%
New Business Royalty Fees (2)$7.9M8%
New Business Commissions (1)$7.5M8%
Other$3.7M4%
Initial Franchise Fees (2)$1.6M2%

MED
MED

Segment breakdown not available.

Related Comparisons